<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00888628</url>
  </required_header>
  <id_info>
    <org_study_id>IAK</org_study_id>
    <nct_id>NCT00888628</nct_id>
  </id_info>
  <brief_title>Study of Islet Transplantation in Type 1 Diabetic Kidney Transplant Recipients</brief_title>
  <official_title>Islet Transplantation in Type 1 Diabetic Kidney Allograft Recipients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Boston Area Diabetes Endocrinology Research Center (funded by NIDDK)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to learn if islet transplantation is an effective treatment for&#xD;
      Type 1 diabetes in people who have had a kidney transplant.&#xD;
&#xD;
      The primary objectives of the study are:&#xD;
&#xD;
      - To set up islet transplantation in patients who have had a kidney transplant and who are&#xD;
      using an immunosuppressive regimen that works&#xD;
&#xD;
      The Secondary objective of the study is:&#xD;
&#xD;
        -  To find out if successful islet transplantation leads to improved metabolic control and&#xD;
           reduced renal complication from diabetes&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will receive (an) infusion(s) of in vitro cultured islets with the goal of achieving&#xD;
      insulin independence. For the first islet transplant, patients will receive induction therapy&#xD;
      with rabbit anti-thymocyte globulin (ATG, 5 doses) and will remain on their maintenance&#xD;
      immunosuppression regimen already in place for their renal allograft. Induction therapy for&#xD;
      subsequent transplants will be 2doses of basiliximab.&#xD;
&#xD;
      All patients will receive Etanercept to promote engraftment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2009</start_date>
  <completion_date type="Actual">August 2016</completion_date>
  <primary_completion_date type="Actual">August 2014</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Insulin Independence With Both an HbA1c ≤ 6.5% and no Severe Hypoglycemic Events at 1 Year After the First Islet Transplant or a Reduction in HbA1c of at Least 1 Point and no Severe Hypoglycemic Events at 1 Year After the First Islet Transplant.</measure>
    <time_frame>1 year after the subject's first islet transplant</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With a Decrease in HbA1c</measure>
    <time_frame>1 year after subject's first islet transplant</time_frame>
    <description>Subjects will have a decrease in HbA1c of at least &gt;1%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stable or Decrease in Urinary Albumin and Creatinine Ratio and Serum Creatinine</measure>
    <time_frame>1 year after subjects initial islet transplant</time_frame>
    <description>Proteinuria and serum creatinine will be stable or decreased as compared to pre-transplant values</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>An Absence Cardiovascular Events, Cerebral Vascular Accident, and Myocardial Infarction</measure>
    <time_frame>1 year after the subject's first islet transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact on Vision</measure>
    <time_frame>1 year after the subject's first islet transplant</time_frame>
    <description>Improvement of frequency of interventions and from changes in reported visual acuity with optical refraction and severity of diabetic retinopathy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absence of Negative Renal Impact Measures</measure>
    <time_frame>1 year after the subject's first islet transplant</time_frame>
    <description>Loss of allograft survivial (return to dialysis, retransplant, death) and Renal allograft function meausred by SCr</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement of Metabolic Control</measure>
    <time_frame>1 year after the subject's first islet transplant</time_frame>
    <description>Whether there is an improvement in metabolic control in IAK will be evaluated based on improvement in&#xD;
basal c-peptide levels,&#xD;
MMTT,&#xD;
insulin requirements, and&#xD;
c-peptide to glucose, creatinine ratio (CPGCR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With a Decrease of Severe Hypoglycemic Events</measure>
    <time_frame>1 year after subject's first transplant</time_frame>
    <description>Subjects will have a decrease in severe hypoglycemic events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction of Insulin Requriements</measure>
    <time_frame>1 year after the subject's first islet transplant</time_frame>
    <description>Evidence of partial success will be considered for subjects who have a reduction in insulin requirements but who are not insulin independent. This will be assessed by comparing the pre-transplant insulin requirement expressed as insulin units per kg per day with the requirement preceding subsequent islet transplants and the insulin requirements at 6 months and 1, 2, and 3 years after the first and last transplant.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Diabetes Mellitus, Type I</condition>
  <arm_group>
    <arm_group_label>Islet transplant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive (an) infusion(s) of in vitro cultured islets with the goal of achieving insulin independence.&#xD;
For the first islet transplant, patients will receive induction therapy with rabbit anti-thymocyte globulin (ATG, 5 doses) and will remain on their maintenance immunosuppression regimen already in place for their renal allograft.&#xD;
Induction therapy for subsequent transplants will be 2 doses of basiliximab.&#xD;
All patients will receive Etanercept to promote engraftment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Purified Pancreatic Islets</intervention_name>
    <description>Islet after kidney transplant in patients with type I diabetes.</description>
    <arm_group_label>Islet transplant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etanercept</intervention_name>
    <description>Given as induction for islet cell transplant</description>
    <arm_group_label>Islet transplant</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male and female subjects&#xD;
&#xD;
          -  Age 18 to 70 years of age&#xD;
&#xD;
          -  Have insulin dependent Diabetes Mellitus Type 1&#xD;
&#xD;
          -  Are post-renal transplant on maintenance immunosuppression with stable renal function&#xD;
&#xD;
          -  HbA1c &gt; 7.5% or &lt; 7.5% and hypoglycemia unawareness&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Weight more than 90 kg&#xD;
&#xD;
          -  Insulin requirement &gt; 60 Units/day&#xD;
&#xD;
          -  Other (non-kidney) organ transplants except prior failed pancreatic graft.&#xD;
&#xD;
          -  Untreated or unstable proliferative diabetic retinopathy&#xD;
&#xD;
          -  Presence of de novo antibody production since the renal allograft or either Class I or&#xD;
             Class II panel-reactive anti-HLA antibodies&#xD;
&#xD;
          -  Active infection&#xD;
&#xD;
          -  Negative screen for Epstein-Barr virus (EBV)&#xD;
&#xD;
          -  Any history of malignancy except for completely resected squamous or basal cell&#xD;
             carcinoma of the skin&#xD;
&#xD;
          -  History of Factor V Leiden mutation&#xD;
&#xD;
          -  Any coagulopathy or medical condition requiring long-term anticoagulant therapy (e.g.&#xD;
             warfarin) after transplantation (low-dose aspirin treatment is allowed) or subjects&#xD;
             with international normalized ratio (INR) &gt; 1.5&#xD;
&#xD;
          -  Severe co-existing cardiac disease&#xD;
&#xD;
          -  Persistent elevation of liver function tests at the time of study entry&#xD;
&#xD;
          -  Acute or chronic pancreatitis&#xD;
&#xD;
          -  Male subjects with elevation of prostate specific antigen&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Positive screen for polyoma (BK) virus&#xD;
&#xD;
          -  Untreated hyperlipidemia&#xD;
&#xD;
          -  Recent hemorrhagic stroke&#xD;
&#xD;
          -  Factors associated with an increased risk of bleeding&#xD;
&#xD;
        Contact PI for complete Incl-Excl criteria list.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James F Markmann, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <study_first_submitted>April 23, 2009</study_first_submitted>
  <study_first_submitted_qc>April 24, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 27, 2009</study_first_posted>
  <results_first_submitted>May 13, 2015</results_first_submitted>
  <results_first_submitted_qc>November 30, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 27, 2017</results_first_posted>
  <last_update_submitted>October 24, 2017</last_update_submitted>
  <last_update_submitted_qc>October 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 29, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>James F. Markmann, MD, PhD</investigator_full_name>
    <investigator_title>Chief Division of Transplantation</investigator_title>
  </responsible_party>
  <keyword>Type I diabetes</keyword>
  <keyword>Islet after Kidney Transplant</keyword>
  <keyword>Islet transplantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etanercept</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Islet Transplant</title>
          <description>Patients will receive (an) infusion(s) of in vitro cultured islets with the goal of achieving insulin independence.&#xD;
For the first islet transplant, patients will receive induction therapy with rabbit anti-thymocyte globulin (ATG, 5 doses) and will remain on their maintenance immunosuppression regimen already in place for their renal allograft.&#xD;
Induction therapy for subsequent transplants will be 2 doses of basiliximab.&#xD;
All patients will receive Etanercept to promote engraftment.&#xD;
Purified Pancreatic Islets: Islet after kidney transplant in patients with type I diabetes.&#xD;
Etanercept: Given as induction for islet cell transplant</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Enrolled</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Screen Failure</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Withdrawn</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Transplanted</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Islet Transplant</title>
          <description>Patients will receive (an) infusion(s) of in vitro cultured islets with the goal of achieving insulin independence.&#xD;
For the first islet transplant, patients will receive induction therapy with rabbit anti-thymocyte globulin (ATG, 5 doses) and will remain on their maintenance immunosuppression regimen already in place for their renal allograft.&#xD;
Induction therapy for subsequent transplants will be 2 doses of basiliximab.&#xD;
All patients will receive Etanercept to promote engraftment.&#xD;
Purified Pancreatic Islets: Islet after kidney transplant in patients with type I diabetes.&#xD;
Etanercept: Given as induction for islet cell transplant</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Insulin Independence With Both an HbA1c ≤ 6.5% and no Severe Hypoglycemic Events at 1 Year After the First Islet Transplant or a Reduction in HbA1c of at Least 1 Point and no Severe Hypoglycemic Events at 1 Year After the First Islet Transplant.</title>
        <time_frame>1 year after the subject's first islet transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Islet Transplant</title>
            <description>Patients will receive (an) infusion(s) of in vitro cultured islets with the goal of achieving insulin independence.&#xD;
For the first islet transplant, patients will receive induction therapy with rabbit anti-thymocyte globulin (ATG, 5 doses) and will remain on their maintenance immunosuppression regimen already in place for their renal allograft.&#xD;
Induction therapy for subsequent transplants will be 2 doses of basiliximab.&#xD;
All patients will receive Etanercept to promote engraftment.&#xD;
Purified Pancreatic Islets: Islet after kidney transplant in patients with type I diabetes.&#xD;
Etanercept: Given as induction for islet cell transplant</description>
          </group>
        </group_list>
        <measure>
          <title>Insulin Independence With Both an HbA1c ≤ 6.5% and no Severe Hypoglycemic Events at 1 Year After the First Islet Transplant or a Reduction in HbA1c of at Least 1 Point and no Severe Hypoglycemic Events at 1 Year After the First Islet Transplant.</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With a Decrease in HbA1c</title>
        <description>Subjects will have a decrease in HbA1c of at least &gt;1%</description>
        <time_frame>1 year after subject's first islet transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Islet Transplant</title>
            <description>Patients will receive (an) infusion(s) of in vitro cultured islets with the goal of achieving insulin independence.&#xD;
For the first islet transplant, patients will receive induction therapy with rabbit anti-thymocyte globulin (ATG, 5 doses) and will remain on their maintenance immunosuppression regimen already in place for their renal allograft.&#xD;
Induction therapy for subsequent transplants will be 2 doses of basiliximab.&#xD;
All patients will receive Etanercept to promote engraftment.&#xD;
Purified Pancreatic Islets: Islet after kidney transplant in patients with type I diabetes.&#xD;
Etanercept: Given as induction for islet cell transplant</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With a Decrease in HbA1c</title>
          <description>Subjects will have a decrease in HbA1c of at least &gt;1%</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Stable or Decrease in Urinary Albumin and Creatinine Ratio and Serum Creatinine</title>
        <description>Proteinuria and serum creatinine will be stable or decreased as compared to pre-transplant values</description>
        <time_frame>1 year after subjects initial islet transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Islet Transplant</title>
            <description>Patients will receive (an) infusion(s) of in vitro cultured islets with the goal of achieving insulin independence.&#xD;
For the first islet transplant, patients will receive induction therapy with rabbit anti-thymocyte globulin (ATG, 5 doses) and will remain on their maintenance immunosuppression regimen already in place for their renal allograft.&#xD;
Induction therapy for subsequent transplants will be 2 doses of basiliximab.&#xD;
All patients will receive Etanercept to promote engraftment.&#xD;
Purified Pancreatic Islets: Islet after kidney transplant in patients with type I diabetes.&#xD;
Etanercept: Given as induction for islet cell transplant</description>
          </group>
        </group_list>
        <measure>
          <title>Stable or Decrease in Urinary Albumin and Creatinine Ratio and Serum Creatinine</title>
          <description>Proteinuria and serum creatinine will be stable or decreased as compared to pre-transplant values</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>An Absence Cardiovascular Events, Cerebral Vascular Accident, and Myocardial Infarction</title>
        <time_frame>1 year after the subject's first islet transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Islet Transplant</title>
            <description>Patients will receive (an) infusion(s) of in vitro cultured islets with the goal of achieving insulin independence.&#xD;
For the first islet transplant, patients will receive induction therapy with rabbit anti-thymocyte globulin (ATG, 5 doses) and will remain on their maintenance immunosuppression regimen already in place for their renal allograft.&#xD;
Induction therapy for subsequent transplants will be 2 doses of basiliximab.&#xD;
All patients will receive Etanercept to promote engraftment.&#xD;
Purified Pancreatic Islets: Islet after kidney transplant in patients with type I diabetes.&#xD;
Etanercept: Given as induction for islet cell transplant</description>
          </group>
        </group_list>
        <measure>
          <title>An Absence Cardiovascular Events, Cerebral Vascular Accident, and Myocardial Infarction</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Impact on Vision</title>
        <description>Improvement of frequency of interventions and from changes in reported visual acuity with optical refraction and severity of diabetic retinopathy</description>
        <time_frame>1 year after the subject's first islet transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Islet Transplant</title>
            <description>Patients will receive (an) infusion(s) of in vitro cultured islets with the goal of achieving insulin independence.&#xD;
For the first islet transplant, patients will receive induction therapy with rabbit anti-thymocyte globulin (ATG, 5 doses) and will remain on their maintenance immunosuppression regimen already in place for their renal allograft.&#xD;
Induction therapy for subsequent transplants will be 2 doses of basiliximab.&#xD;
All patients will receive Etanercept to promote engraftment.&#xD;
Purified Pancreatic Islets: Islet after kidney transplant in patients with type I diabetes.&#xD;
Etanercept: Given as induction for islet cell transplant</description>
          </group>
        </group_list>
        <measure>
          <title>Impact on Vision</title>
          <description>Improvement of frequency of interventions and from changes in reported visual acuity with optical refraction and severity of diabetic retinopathy</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absence of Negative Renal Impact Measures</title>
        <description>Loss of allograft survivial (return to dialysis, retransplant, death) and Renal allograft function meausred by SCr</description>
        <time_frame>1 year after the subject's first islet transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Islet Transplant</title>
            <description>Patients will receive (an) infusion(s) of in vitro cultured islets with the goal of achieving insulin independence.&#xD;
For the first islet transplant, patients will receive induction therapy with rabbit anti-thymocyte globulin (ATG, 5 doses) and will remain on their maintenance immunosuppression regimen already in place for their renal allograft.&#xD;
Induction therapy for subsequent transplants will be 2 doses of basiliximab.&#xD;
All patients will receive Etanercept to promote engraftment.&#xD;
Purified Pancreatic Islets: Islet after kidney transplant in patients with type I diabetes.&#xD;
Etanercept: Given as induction for islet cell transplant</description>
          </group>
        </group_list>
        <measure>
          <title>Absence of Negative Renal Impact Measures</title>
          <description>Loss of allograft survivial (return to dialysis, retransplant, death) and Renal allograft function meausred by SCr</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Improvement of Metabolic Control</title>
        <description>Whether there is an improvement in metabolic control in IAK will be evaluated based on improvement in&#xD;
basal c-peptide levels,&#xD;
MMTT,&#xD;
insulin requirements, and&#xD;
c-peptide to glucose, creatinine ratio (CPGCR).</description>
        <time_frame>1 year after the subject's first islet transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Islet Transplant</title>
            <description>Patients will receive (an) infusion(s) of in vitro cultured islets with the goal of achieving insulin independence.&#xD;
For the first islet transplant, patients will receive induction therapy with rabbit anti-thymocyte globulin (ATG, 5 doses) and will remain on their maintenance immunosuppression regimen already in place for their renal allograft.&#xD;
Induction therapy for subsequent transplants will be 2 doses of basiliximab.&#xD;
All patients will receive Etanercept to promote engraftment.&#xD;
Purified Pancreatic Islets: Islet after kidney transplant in patients with type I diabetes.&#xD;
Etanercept: Given as induction for islet cell transplant</description>
          </group>
        </group_list>
        <measure>
          <title>Improvement of Metabolic Control</title>
          <description>Whether there is an improvement in metabolic control in IAK will be evaluated based on improvement in&#xD;
basal c-peptide levels,&#xD;
MMTT,&#xD;
insulin requirements, and&#xD;
c-peptide to glucose, creatinine ratio (CPGCR).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With a Decrease of Severe Hypoglycemic Events</title>
        <description>Subjects will have a decrease in severe hypoglycemic events</description>
        <time_frame>1 year after subject's first transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Islet Transplant</title>
            <description>Patients will receive (an) infusion(s) of in vitro cultured islets with the goal of achieving insulin independence.&#xD;
For the first islet transplant, patients will receive induction therapy with rabbit anti-thymocyte globulin (ATG, 5 doses) and will remain on their maintenance immunosuppression regimen already in place for their renal allograft.&#xD;
Induction therapy for subsequent transplants will be 2 doses of basiliximab.&#xD;
All patients will receive Etanercept to promote engraftment.&#xD;
Purified Pancreatic Islets: Islet after kidney transplant in patients with type I diabetes.&#xD;
Etanercept: Given as induction for islet cell transplant</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With a Decrease of Severe Hypoglycemic Events</title>
          <description>Subjects will have a decrease in severe hypoglycemic events</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Reduction of Insulin Requriements</title>
        <description>Evidence of partial success will be considered for subjects who have a reduction in insulin requirements but who are not insulin independent. This will be assessed by comparing the pre-transplant insulin requirement expressed as insulin units per kg per day with the requirement preceding subsequent islet transplants and the insulin requirements at 6 months and 1, 2, and 3 years after the first and last transplant.</description>
        <time_frame>1 year after the subject's first islet transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Islet Transplant</title>
            <description>Patients will receive (an) infusion(s) of in vitro cultured islets with the goal of achieving insulin independence.&#xD;
For the first islet transplant, patients will receive induction therapy with rabbit anti-thymocyte globulin (ATG, 5 doses) and will remain on their maintenance immunosuppression regimen already in place for their renal allograft.&#xD;
Induction therapy for subsequent transplants will be 2 doses of basiliximab.&#xD;
All patients will receive Etanercept to promote engraftment.&#xD;
Purified Pancreatic Islets: Islet after kidney transplant in patients with type I diabetes.&#xD;
Etanercept: Given as induction for islet cell transplant</description>
          </group>
        </group_list>
        <measure>
          <title>Reduction of Insulin Requriements</title>
          <description>Evidence of partial success will be considered for subjects who have a reduction in insulin requirements but who are not insulin independent. This will be assessed by comparing the pre-transplant insulin requirement expressed as insulin units per kg per day with the requirement preceding subsequent islet transplants and the insulin requirements at 6 months and 1, 2, and 3 years after the first and last transplant.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Islet Transplant</title>
          <description>Patients will receive (an) infusion(s) of in vitro cultured islets with the goal of achieving insulin independence.&#xD;
For the first islet transplant, patients will receive induction therapy with rabbit anti-thymocyte globulin (ATG, 5 doses) and will remain on their maintenance immunosuppression regimen already in place for their renal allograft.&#xD;
Induction therapy for subsequent transplants will be 2 doses of basiliximab.&#xD;
All patients will receive Etanercept to promote engraftment.&#xD;
Purified Pancreatic Islets: Islet after kidney transplant in patients with type I diabetes.&#xD;
Etanercept: Given as induction for islet cell transplant</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea and Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic Reaction (Elevated Temp 104.7)</sub_title>
                <description>Elevated temp during Thymoglobulin infusion</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Soft tissue infection</sub_title>
                <description>Soft tissue infection of foot. This is an exacerbation of a pre-existing condition</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertenstion</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper Respiratory Infection</sub_title>
                <counts group_id="E1" events="5" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <description>Recurrent UTIs at baseline</description>
                <counts group_id="E1" events="7" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <counts group_id="E1" events="11" subjects_affected="3" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Elevated Creatinine</sub_title>
                <description>Elevated Creatinine, resolved.</description>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>James F. Markmann, M.D. Ph.D - Chief, Division of Transplant Surgery</name_or_title>
      <organization>Massachusetts General Hospital</organization>
      <phone>617-643-4087</phone>
      <email>kcrisalli@mgh.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

